Freeline Therapeutics company

Freeline Therapeutics is a biopharmaceutical company that develops liver directed gene therapies for bleeding disorders and other diseases. Its therapies are based on next-generation proprietary AAV vector platform, with its lead program being a gene therapy to treat haemophilia B.
Freeline Therapeutics was founded in 2015 and is headquartered in London, England.
Technology: P4 Medicine
Industry: Personalized Medicine
Headquarters: Stevenage, Herefordshire, United Kingdom
Founded Date: 2015
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 9
Total Funding: $276M
Estimated Revenue: $1M to $10M
Last Funding Type: Series C

Visit Website
Register and Claim Ownership